肠道微生物组在多发性硬化症中的作用:从病因到治疗。

3区 医学 Q2 Medicine
International review of neurobiology Pub Date : 2022-01-01 Epub Date: 2022-06-25 DOI:10.1016/bs.irn.2022.06.001
Shailesh K Shahi, Meeta Yadav, Sudeep Ghimire, Ashutosh K Mangalam
{"title":"肠道微生物组在多发性硬化症中的作用:从病因到治疗。","authors":"Shailesh K Shahi, Meeta Yadav, Sudeep Ghimire, Ashutosh K Mangalam","doi":"10.1016/bs.irn.2022.06.001","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS that affects around one million people in the United States. Predisposition or protection from this disease is linked with both genetic and environmental factors. In recent years, gut microbiome has emerged as an important environmental factor in the pathobiology of MS. The gut microbiome supports various physiologic functions, including the development and maintenance of the host immune system, the perturbation of which is known as dysbiosis and has been linked with multiple diseases including MS. We and others have shown that people with MS (PwMS) have gut dysbiosis that is characterized by specific gut bacteria being enriched or depleted. Consequently, there is an emphasis on determining the mechanism(s) through which gut bacteria and/or their metabolites alter the course of MS through their ability to provide protection, predispose individuals, or promote disease progression. Improving our understanding of these mechanisms will allow us to harness the enormous potential of the gut microbiome as a diagnostic and/or therapeutic agent. In this chapter, we will discuss current advances in microbiome research in the context of MS, including a review of specific bacteria that are currently linked with this disease, potential mechanisms of disease pathogenesis, and the utility of microbiome-based therapy for PwMS.</p>","PeriodicalId":14468,"journal":{"name":"International review of neurobiology","volume":" ","pages":"185-215"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role of the gut microbiome in multiple sclerosis: From etiology to therapeutics.\",\"authors\":\"Shailesh K Shahi, Meeta Yadav, Sudeep Ghimire, Ashutosh K Mangalam\",\"doi\":\"10.1016/bs.irn.2022.06.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS that affects around one million people in the United States. Predisposition or protection from this disease is linked with both genetic and environmental factors. In recent years, gut microbiome has emerged as an important environmental factor in the pathobiology of MS. The gut microbiome supports various physiologic functions, including the development and maintenance of the host immune system, the perturbation of which is known as dysbiosis and has been linked with multiple diseases including MS. We and others have shown that people with MS (PwMS) have gut dysbiosis that is characterized by specific gut bacteria being enriched or depleted. Consequently, there is an emphasis on determining the mechanism(s) through which gut bacteria and/or their metabolites alter the course of MS through their ability to provide protection, predispose individuals, or promote disease progression. Improving our understanding of these mechanisms will allow us to harness the enormous potential of the gut microbiome as a diagnostic and/or therapeutic agent. In this chapter, we will discuss current advances in microbiome research in the context of MS, including a review of specific bacteria that are currently linked with this disease, potential mechanisms of disease pathogenesis, and the utility of microbiome-based therapy for PwMS.</p>\",\"PeriodicalId\":14468,\"journal\":{\"name\":\"International review of neurobiology\",\"volume\":\" \",\"pages\":\"185-215\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International review of neurobiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.irn.2022.06.001\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/6/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International review of neurobiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.irn.2022.06.001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

多发性硬化症(MS)是一种中枢神经系统的慢性炎症性疾病,在美国大约有100万人受到影响。易患或预防这种疾病与遗传和环境因素有关。近年来,肠道微生物组已成为多发性硬化症病理生物学中的一个重要环境因素。肠道微生物组支持多种生理功能,包括宿主免疫系统的发育和维持,其扰动被称为生态失调,并与包括多发性硬化症在内的多种疾病有关。我们和其他人已经表明,多发性硬化症(PwMS)患者存在肠道生态失调,其特征是特定的肠道细菌被富集或耗尽。因此,重点是确定肠道细菌和/或其代谢物通过提供保护、使个体易感性或促进疾病进展而改变MS病程的机制。提高我们对这些机制的理解将使我们能够利用肠道微生物组作为诊断和/或治疗药物的巨大潜力。在本章中,我们将讨论MS背景下微生物组研究的最新进展,包括目前与该疾病相关的特定细菌的综述,疾病发病的潜在机制,以及基于微生物组的治疗PwMS的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Role of the gut microbiome in multiple sclerosis: From etiology to therapeutics.

Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS that affects around one million people in the United States. Predisposition or protection from this disease is linked with both genetic and environmental factors. In recent years, gut microbiome has emerged as an important environmental factor in the pathobiology of MS. The gut microbiome supports various physiologic functions, including the development and maintenance of the host immune system, the perturbation of which is known as dysbiosis and has been linked with multiple diseases including MS. We and others have shown that people with MS (PwMS) have gut dysbiosis that is characterized by specific gut bacteria being enriched or depleted. Consequently, there is an emphasis on determining the mechanism(s) through which gut bacteria and/or their metabolites alter the course of MS through their ability to provide protection, predispose individuals, or promote disease progression. Improving our understanding of these mechanisms will allow us to harness the enormous potential of the gut microbiome as a diagnostic and/or therapeutic agent. In this chapter, we will discuss current advances in microbiome research in the context of MS, including a review of specific bacteria that are currently linked with this disease, potential mechanisms of disease pathogenesis, and the utility of microbiome-based therapy for PwMS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.90
自引率
0.00%
发文量
75
审稿时长
>12 weeks
期刊介绍: Published since 1959, International Review of Neurobiology is a well-established series appealing to neuroscientists, clinicians, psychologists, physiologists and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信